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Abstract
Background: Parkinson’s disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5
million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural
instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral
symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10
years ago, there was lack of standardization for the management of PD in different regions and among different
physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese
Parkinson’s Disease and Movement Disorder Society have published three versions of guidelines for the
management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment
for PD in China improved.
Objectives: To update the treatment guidelines based on current foreign and domestic practice guidelines and
clinical evidence, and to improve the treatment options available to physicians in the management of PD.
Summary: A variety of treatment recommendations in the treatment guidelines have been proposed, including
physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The
principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a
satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications.
Moreover, different treatment strategies should be considered at different stages of the disease. Importantly,
treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations
has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
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Background
Parkinson’s disease (PD) is the second most common
age-dependent neurodegenerative disorder, affecting ap-
proximately 1.7 % of the population over 65 years old in
China [1, 2]. A variety of environmental, genetic, im-
munological cues, including excessive oxidative stress,
have been proposed to be associated with the onset of
this disease [3]. The defining neuropathological features
of PD are the preferential loss of dopaminergic (DA)
neurons and the formation of Lewy bodies in the sub-
stantia nigra pars compacta (SNpc) [3]. However, the
molecular mechanism underlying neurodegeneration in
PD is not fully understood. The clinical manifestations
of PD include motor symptoms, e.g., resting tremor,
muscular rigidity, bradykinesia, and postural instability;
and non-motor symptoms, e.g., hyposmia, rapid eye
movement (REM) sleep behavior disorder, constipation
and depression [3–6].
The motor symptoms of PD can be alleviated by drugs
that enhance dopamine function, including levodopa,
dopamine agonists, type B monoamine oxidase (MAO-
B) inhibitors, catechol O-methyl transferase (COMT)
inhibitors, amantadine and benzhexol. Among these, levo-
dopa is considered the most effective. However, chronic
use of these drugs leads to loss of their therapeutic effica-
cies and motor complications. In addition, some of non-
motor symptoms of PD cannot be improved significantly
and comprehensively using these drugs.
Motor and non-motor symptoms markedly affect the
quality of life of PD patients. Optimized treatment is es-
sential to improve symptoms and enhancing the quality
of life of PD patients. During the past 10 years, we have
developed three treatment guidelines for PD patients in
China in 2006, 2009, and 2014, respectively [7–9]. The
implementation of these guidelines has promoted greatly
the standardization and optimization of the management
of PD patients in China. Here, we provide updated treat-
ment guidelines to assist physicians to improve and




PD patients can present sequentially or simultaneously
with either motor or non-motor symptoms. However,
these symptoms could be present in the patients
throughout their treatment and affect the quality of the
patient’s life. Therefore, comprehensive treatment for
both motor and non-motor symptoms should be imple-
mented. The recommended therapeutic strategies in-
clude medication, surgical intervention, physical activity
and other rehabilitation, psychological counseling, and
caring and nursing assistance. Medication is recom-
mended as the first option for PD treatment, and is
considered the key approach throughout the course of
treatment, whereas surgery is suggested as an effective
supplement to medication. However, the currently used
therapeutic strategies can only improve the symptoms of
PD patients, without modifying or curing the disease.
Therefore, the management of PD should focus not only
on immediate management, but also on long-term man-
agement, to obtain long-term benefits for patients.
Principles of medication
Both motor and non-motor symptoms can affect the
working ability and quality of life in PD patients; there-
fore, it is recommended that the principles of medication
should aim at effectively improving symptoms, working
ability and quality of life. Physical activity and disease-
modifying medication should be initiated at the early-
stage of the disease, which could not only alleviate the
symptoms, but also delay the progression of the disease.
The principles of dosage titration should be followed to
avoid acute adverse reactions to the drugs, achieve a sat-
isfactory clinical effect with a low dose and reduce the
incidence of motor complications. Interestingly, the inci-
dence of dyskinesia in Chinese PD patients is signifi-
cantly lower than that in Western countries [10–12].
In addition, the treatment of PD should be based on
evidence-based medicine; however, personalized medi-
cine is advocated. In other words, to make a decision on
a medication, a comprehensive assessment of the patient
is required, including the dominant symptoms, disease
severity, as well as a variety of factors, such as cognitive
condition, age of onset of the disease, employment sta-
tus, comorbidities, adverse effects of the drugs, the pa-
tients preferred drug selection and economic status.
Every effort should be made to avoid, delay and reduce
the acute side effects, as well as the chronic motor compli-
cations. Anti-PD drugs, particularly levodopa, should not
be discontinued abruptly to avoid the occurrence of the
symptom aggravation or malignant withdrawal syndrome.
Pharmaceutical therapies
PD can be classified according to disease severity, into
the early stage (Hoehn − Yahr: 1 − 2.5) and the advanced
stage (Hoehn − Yahr: 3 − 5). Therapeutic options are sug-
gested for the treatment of early stage and advanced
stage of PD, independently.
Treatment of early-stage PD
PD progresses gradually with time. Clinical evidence in-
dicates that PD progresses faster in the early stage than
in the advanced stage. Therefore, once diagnosed in the
early stage, treatment, particularly disease-modifying
medication or physical activity, is required as early as
possible to make optimally use of the best time window
in PD progression. The treatment of early stage PD
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should be divided into drug treatment and non-drug
treatment (including physical activity, adding knowledge
of the disease, providing nutritional supplementation, in-
creasing building up confidence regarding conquering
the disease, and gaining support from family and society).
At the early stage, monotherapy is usually considered;
however, combined therapy in minimal doses can also be
adopted to achieve the goals with the best therapeutic ef-
fect, and to maintain a long-term impact to reduce the in-
cidence of motor complications as much as possible.
Medication includes using disease-modifying drugs
and symptom-treating drugs. In addition to the capacity
for disease modification, disease-modifying drugs can
also improve symptoms, while some symptom-treating
drugs might also have disease-modifying effects.
The purpose of using disease-modifying drugs is to delay
disease progression. Clinically, the most commonly used
disease-modifying drugs include monoamine oxidase-B
(MAO-B) inhibitors and dopamine agonists. Clinical trials
indicated that an MAO-B inhibitor (selegiline) combined
with tocopherol (the DATATOP trial) and rasagiline (the
ADAGIO trial) could delay the progression of PD [13, 14].
Furthermore, it was suggested that dopamine agonists,
such as pramipexole (the CALM-PD trial) and ropinirole
(the REAL-PET trial), might have disease-modifying effects
[15, 16]. However, there is insufficient evidence to show
that these drugs have disease-modifying effects.
Principles of drug selection
(1) Recommendations for the management of early-onset
PD patients without cognitive impairment (Fig. 1)
include:① non-ergot dopamine agonists;②MAO-B
inhibitors alone, or together with tocopherol;③
Amantadine;④ levodopa plus decarboxylase
inhibitors (levodopa/benserazide or levodopa/
carbidopa);⑤ Stalevo (levodopa/carbidopa + COMT
inhibitor); and⑥ anticholinergics (benzhexol).
The principles of drug selection are not dependent
on the sequence of the above recommendations;
instead, the choice should be only based on the
particular condition of each PD patient. It is
recommended to start with non-ergot dopamine
agonists, MAO-B inhibitors, or Stalevo, for
early-onset young patients. Dopamine agonists,
especially pramipexole, are recommended as
preferable for tremor-dominant patients or PD
patients with depression, while MAO-B inhibitors
are recommended as preferable for PD patients with
gait disorders. Amantadine can be initially used if it
is economically infeasible to start with expensive
drugs. For patients with special occupations, or
for the purpose of significantly improving motor
symptoms, or upon cognitive decline, it is
recommended to start with levodopa plus
decarboxylase inhibitors, or Stalevo. Additionally,
the minimal dose of dopamine agonists, MAO-B
inhibitors, or amantadine can be co-applied with
a minimal dose of levodopa plus decarboxylase
inhibitors. For patients with severe tremor-dominant
symptoms, anticholinergics (such as benzhexol)
could be used when other anti-PD drugs are not
effective; however, the related side effects must be
closely monitored.
(2) Recommendations for the management of late-
onset PD patients or early-onset PD patients with
cognitive impairment. Levodopa plus decarboxylase
inhibitors are recommended as the first choice
medication. However, with the progression of the
disease, dopamine agonists, MAO-B inhibitors, or
COMT inhibitors could be considered as add-on
therapies (Fig. 2). Benzhexol is not recommended
because of possible severe adverse effects, particu-
larly for older male patients.
Therapeutic drugs options
(1) Levodopa plus decarboxylase inhibitors. The
recommended initial dosage is 62.5 − 125 mg two
times or three times per day (b.i.d, or t.i.d) and the
dosage needs to be increased gradually as the disease
progresses, until symptoms improve, or the
appropriate dosage sustained until adverse effects
are absent. The drug should be taken one hour
before meals or one and half hour after meals. In the
past, a delay in the use of levodopa was
recommended, because dyskinesia could be induced
by early use of levodopa. However, the principle of
early used low dose had been proposed for many years
in China and several studies provided evidence that
early use of a low dose (≤400 mg/d) of levodopa did
not increase the incidence of dyskinesia [10, 11, 17],
which was supported by the results of Olanow’s study
[12]. Immediate-release levodopa/benserazide or
levodopa/carbidopa shows fast acting effects, while
controlled-release levodopa/benserazide or levodopa/
carbidopa produces slow acting effects with low
bioavailability. Therefore, patients should be careful
when taking the two different types of drugs.
Furthermore, they should be used with caution in
patients with active peptic ulcers, and should be
avoided in patients with narrow cleft glaucoma or
mental disorders. The dispersible formulation of
levodopa/benserazide is easy to use and shows rapid
therapeutic efficacy after ingestion. Thus, it is
recommended for PD patients with morning akinesia,
delayed onset of “on” time, afternoon “off” status, and
dysphagia [18].
(2) Dopamine agonists. Non-ergot dopamine agonists
are the most commonly used first-choice drugs
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Fig. 2 Pathway for combined therapy in early Parkinson’s disease
Fig. 1 Pathway for monotherapy in early Parkinson’s disease
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[19–24], and are particularly suitable for early-stage
PD patients. Their long half-lives mean that
such drugs could avoid pulse stimulation on the
striatal postsynaptic membrane, thereby probably
preventing or decreasing the likelihood of motor
complications. Dopamine agonists should be started
at lower doses, and then increased slowly until the
dosage is reached that shows both a satisfactory
effect and the absence of adverse effects. The
adverse reactions to dopamine agonists are similar
to those found with levodopa. However, dopamine
agonists have a lower incidence of motor fluctuation
and dyskinesia and a higher incidence of orthostatic
hypotension, ankle edema, and mental disorders
(illusion, bulimia and hypersexuality). There are two
types of dopamine agonists: ergot dopamine agonists
(bromocriptine, pergolide, dihydroergocryptine,
cabergoline and lisuride) and non-ergot dopamine
agonists (pramipexole, ropinirole, piribedil,
rotigotine and apomorphine). Ergot dopamine
agonists are currently not recommended because
of their potential severe adverse reactions, such as
valvular disorder and fibrosis of the lung pleura
[25–27]. Thus, pergolide has already been
discontinued in China. These severe adverse
reactions to pergolide were rarely found in China,
because of lower dosage used compared with
Western countries. Currently, the most commonly
used non-ergot dopamine agonists recommended in
China are pramipexole and sustained-release
piribedil. They have been used for over 10 years.
Ropinirole is now available for use in the clinic. A
multi-center clinical trial of rotigotine has been
completed and it will soon be available for clinical use.
① Pramipexole: There are two types of formulations:
immediate-release pramipexole and extended-
release pramipexole. For immediate-release
pramipexole, the initial dosage is 0.125 mg, t.i.d.;
this should then be increased by 0.125 mg, t.i.d., on
a weekly basis. The usual clinically effective dose is
1.5 − 2.25 mg/d, up to a maximum
dosage of 4.5 mg/day; however, very few Chinese
patients take this dosage [24]. A randomized,
double-blind, double-dummy, parallel-group study
of the efficacy and safety of extended-release prami-
pexole versus immediate-release
pramipexole conducted in Chinese PD patients
showed similar efficacy and safety profiles.
Immediate-release pramipexole can be switched
to extended-release pramipexole overnight or
gradually over a few days at the same daily
dose [24, 28].
② Sustained-release piribedil: The initial dosage is
50 mg q.d or 25 mg b.i.d. during the first week,
which is then increased to 50 mg, b.i.d., from the
second week on. The usual clinically effective
dose is 50 mg, t.i.d., and the maximal dosage is
250 mg/day; however, very few Chinese patients
take this dose.
The forthcoming non-ergot dopamine agonists
recommended in China are ropinirole and
rotigotine.
③ Ropinirole: The initial dosage is 0.25 mg, t.i.d.,
which can be increased each week until the
dosage reaches 1.0 mg, t.i.d. The usual clinically
effective dose is 1.0 − 3.0 mg, t.i.d., and the
maximal daily dosage (24 mg/day), which has
been used in a few Chinese patients [29].
④ Rotigotine: The initial dosage should be 2 mg,
one time per day (q.d.), which may be increased
by 2 mg weekly. The usual clinically effective dose
is 6 − 8 mg/day for early-stage patients and 8 −
16 mg for advanced-stage patients [30].
The ergot dopamine agonists, including
bromocriptine and α-Dihydroergocryptine, are
currently available in China but they are now not
recommended in Chinese PD patients.
(3) MAO-B inhibitors. These include selegiline and
rasagiline. They are recommended for the treatment
of both early stage and advanced stage PD,
particularly in the early onset or de novo patients.
An initial dosage of selegiline is 2.5–5 mg, b.i.d.,
which should be taken in the morning and at noon,
but not in the evening to avoid insomnia, or can be
taken together with tocopherol (2,000 IU) [13]. The
recommended dosage of rasagiline is 1.0 mg, q.d.
after breakfast [31, 32]. These should be used with
caution in patients with gastric ulcers, and taking
them together with 5-hydroxytryptamine-selective
serotonin reuptake inhibitors should be avoided,
because of possible severe adverse reactions [33, 34].
(4) COMT inhibitors. One of the main causes of motor
complications is the “pulse” - like stimulation of the
striatal postsynaptic dopamine receptor. COMT
inhibitors produce sustained dopaminergic
stimulation on striatal postsynaptic dopamine
receptor. The combination of entacapone/levodopa/
carbidopa, i.e., Stalevo, is recommended for the early
stage of PD to improve symptoms and to prevent or
delay the onset of motor complications [35].
However, it is controversial whether early-stage
use of Stalevo can delay the onset of motor
complications or increase the incidence of
dyskinesia; this awaits further validation [36]. For
advanced stage patients, entacapone or tolcapone
can be added as an adjunct therapy when the
therapeutic effects of levodopa/benseraside or
levodopa/carbidopa decline [17]. The dosage of
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entacapone is 100 − 200 mg/time, and the
frequency of administration is similar to that of
levodopa/benseraside or levodopa/carbidopa
[36, 37]. It is recommended that entacapone be
taken together with levodopa/benseraside or
levodopa/carbidopa. The dosage of tolcapone is
100 mg, t.i.d., and the first dosage should be taken
together with levodopa/benseraside or levodopa/
carbidopa and should be repeated every 6 h, or it
can be used alone, at a maximum dosage of 600 mg
per day [38]. The adverse reactions to COMT
inhibitors include diarrhea, headache, sweating,
dry mouth, increased alanine aminotransferase,
abdominal pain and discoloured urinecolor yellow.
Tolcapone could lead to liver damage; therefore,
liver function should be monitored closely,
particularly in the first 3 months of use.
(5) Amantadine. It is recommended to start amantadine
at a dosage of 50 − 100 mg b.i.d.; the patient should
take the last dose before 4:00 PM. Amantadine can
improve hypokinesia, rigidity and tremor, and can
also improve dyskinesia (Level C evidence). Caution
should be taken in using amantadine in PD patients
with renal insufficiency, epilepsy, severe ulcers and liver
disease. It should never be taken by lactating women.
(6) Anticholinergics. Benzhexol (1 − 2 mg, t.i.d.) is the
most commonly used anticholinergic drug in China,
mainly in early-onset young patients, but not in
elderly patients. It is recommended that this be
applied only in young patients with tremor-
dominant symptoms, usually when other anti-PD
drugs are not effective. For patients aged < 60 years,
patients should be informed that long-term use
of benzhexol could result in cognitive decline;
thus, regular examination of cognitive function is
required. Once cognitive decline is confirmed, the
drug should be discontinued promptly. Usually,
benzhexol is not recommended for PD patients
aged ≥ 60 years. Its use is contraindicated for
patients with narrow angle glaucoma or prostatic
hypertrophy.
Treatment of advanced-stage PD
The treatment of advanced-stage PD is extremely compli-
cated, involving the progression of the disease, the decline
of therapeutic effects, and adverse reactions or motor
complications after chronic use of medication [39, 40]. To
treat patients with advanced PD, it is recommended that
physicians aim to improve motor symptoms and manage
motor complications and non-motor symptoms.
Management of motor complications
Motor complications, including motor and non-motor
symptom fluctuations and dyskinesias, are presented
frequently in advanced-stage PD [41, 42]. Adjusting the
dosage or frequency of medication can improve symp-
tom fluctuations or dyskinesias. Moreover, surgical inter-
vention, such as deep brain stimulation (DBS), can also
be effective [20, 35, 43–46].
Management of symptom fluctuations
The common symptom fluctuations include the
wearing-off and the on − off phenomena. It is recom-
mended that the wearing-off phenomenon can be man-
aged using several approaches (Table 1).
The management of the on − off phenomenon is very
complicated. It is recommended that treatment is started
with long half-life dopamine agonists orally, or continuous
micropump infusion of levodopa methyl ester, ethyl ester,
or dopamine agonists (such as lisuride) [19, 35, 43–45, 47].
Management of dyskinesias
Dyskinesia includes peak-dose dyskinesia, biphasic
dyskinesia, and dystonia. Several approaches are recom-
mended to manage peak-dose dyskinesia (Table 2).
Several approaches are recommended to manage
biphasic dyskinesias (Table 3).
Continuous micropump infusion of dopamine agonists,
levodopa methyl or ethyl ester can improve both dyskine-
sias and symptom fluctuations. However, it is still under
investigation whether oral preparations can achieve simi-
lar effects. Other drugs for the treatment of dyskinesias,
including adenosine A2A receptor antagonists, which tar-
get non-DA receptors in the basal ganglia, are currently in
clinical trials.
Table 1 Recommendation for the management of the wearing-off
phenomenon
① Increase the frequency of drug taking with the same daily dose, or
appropriately increase the total daily dose.
② Switch immediate-release levodopa to controlled-release levodopa or
extended-release levodopa to prolong the action of levodopa. They are
more appropriate for the wearing-off phenomenon in early-stage PD.
The dosage of controlled-release levodopa should be
increased by 20 − 30 % after switching from immediate-release
levodopa, because of its low bioavailability. The US guidelines
reported that this could not decrease the off stage (Level C evidence)
[44], while the UK NICE guidelines recommended this application in
advanced-stage PD, but not as the first choice (Level B evidence) [92].
③ Add long half-life dopamine agonists, including pramipexole and
ropinirole (Level B evidence), cabergoline and apomorphine (Level C
evidence) [44]; however, bromocriptine could not shorten the off stage
(Level C evidence) [44]. Other dopamine agonists could be used to
replace the currently used dopamine agonists that lose their efficacy.
④ Add COMT inhibitors to generate continuous dopaminergic
stimulation to the striatum, including entacapone (Level A evidence)
and tolcapone (Level B evidence) [44].
⑤ Add MAO-B inhibitors, such as rasagiline (Level A evidence) and
selegiline (Level C evidence) [44].
⑥ Minimize the impact of protein diet on the uptake and blood − brain
barrier crossing of levodopa. Drugs should be taken 1 h before or 1.5 h
after meals.
⑦ Surgical intervention, such as DBS of the subthalamic nucleus (STN)
(Level C evidence), is helpful.
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For the management of morning dystonia, it is recom-
mended to add controlled-release levodopa other than
immediate-release levodopa, or long-acting dopamine
agonists at night, and take an immediate-release levo-
dopa other than controlled-release levodopa, especially
madopar dispersible, before getting up in the morning.
The management of on-dystonia is similar to that of
peak-dose dyskinesia. Surgical intervention, such as
DBS, can be beneficial to manage dyskinesias [48–52].
Management of postural instability
Postural instability is the most common cause of falling
in advanced-stage PD patients, which occurs easily dur-
ing postural changes such as turning around, getting up
or bending down. Currently there are no effective thera-
peutic approaches, although adjusting the dosage or add-
ing other drugs may occasionally help. In the initial
stages, it may be beneficial to adjust the center of gravity
(by stepping, striding and walking), to listen to com-
mands, music or beating rhythms, or to stride across ob-
jects [53]. When necessary, effective supervision and
care, as well as the use of walking aids or wheelchairs,
are needed.
Management of non-motor symptoms
The non-motor symptoms are very common clinical
manifestations in advanced-stage PD patients. They in-
clude sensory disorders, mental disorders, autonomic
dysfunction and sleep disorders, which require active
management and treatment [54, 55].
①Management of mental disorders. The most
common mental disorders in advanced-stage PD
are depression and/or anxiety, illusion, cognitive
disorders and dementia. First, it should be identified
whether anti-PD drugs induce the symptoms or
whether they are caused by the disease itself. For
drug-induced symptoms of mental disorders, it
is recommended that the drugs be reduced or
discontinued, based on risk in the following order:
anticholinergics, amantadine, MAO-B inhibitors
and dopamine agonists. If the symptoms persist
after taking the above measures, it may be necessary
to reduce the dosage of levodopa/benseraside or
levodopa/carbidopa gradually without aggravating
the PD motor symptoms. If no satisfactory response
is gained after adjusting the dosage, this would
indicate that the disease itself might be causing the
symptoms. Therefore, the drug therapy for mental
disorders should be considered. For patients with
hallucinations and illusions, clozapine or quetiapine
is recommended. Clozapine has a slightly stronger
effect than quetiapine, but there is a slight
likelihood of agranulocytosis (1–2 %). Thus, close
monitoring of the blood count is necessary. The
use of antipsychotics (APs) is associated with an
increased risk of mortality in patients with PD;
quetiapine was associated with the lowest (but still
elevated) risk [56]. Pimavanserin, a selective inverse
agonist of the 5-hydroxytryptamine 2A (5-HT2A)
receptor, has been approved by the United States
Food and Drug Administration [57]. Data from
phase II and phase III clinical trials suggest that
pimavanserin is a safe and effective treatment option
for psychosis in PD patients [58, 59]. Trial results
indicate a significant reduction in hallucinations
and delusions in PD patients with psychosis,
without worsening motor symptoms [58, 59]. For
the treatment of depression and/or anxiety, it is
recommended that dopamine agonists, especially
pramipexole, which can both improve the motor
symptoms and depression, or selective serotonin
reuptake inhibitors, be used. Lorazepam and
diazepam are highly effective for irritability.
Cholinesterase inhibitors, such as rivastigmine and
donepezil, and memantine are recommended to
treat cognitive disorders and dementia. Rivastigmine
is recommended as the first choice [60–62].
②Management of autonomic dysfunction. The most
common symptoms of autonomic dysfunction
include constipation, urinary dysfunction and
orthostatic hypotension. To improve constipation,
adequate intake of fluid, fruits, vegetables, fiber and
lactulose (10–20 g/day) or other mild cathartics,
Chinese traditional medicine, (including rhubarb,
aloe, long hui pill and folium sennae) might be
helpful. Adding gastric dynamic drugs, such as
Table 2 Recommendation for the management of peak-dose
dyskinesia
① Reduce the single dose of levodopa/benseraside or levodopa/
carbidopa per time; or appropriately add dopamine agonists or
COMT inhibitors if the motor symptoms deteriorate after the dose of
levodopa is reduced.
② Add amantadine (Level C evidence) [44].
③ Add atypical neuroleptics, such as clozapine, but start with an
initial low dosage and then increase gradually, and closely monitor
granulocytes.
④ Replace controlled-release levodopa with immediate-release levo-
dopa to avoid the cumulative effects of controlled-release levodopa,
which can aggravate dyskinesia.
Table 3 Recommendation for the management of biphasic
dyskinesias
① Replace controlled-release levodopa with immediate-release levodopa,
preferably with madopar dispersible, which can be used to manage the
beginning-of-dose dyskinesia.
② Add long half-life dopamine agonists or COMT inhibitors, which
can extend the half-life of plasma levodopa, thus increasing the area
under the curve, and relieving the end-of-dose dyskinesia. This may
also benefit the beginning-of-dose dyskinesia.
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domperidone or mosapride, might also be beneficial.
It is recommended that anticholinergics be
discontinued if they are used together with other
anti-parkinsonian drugs. For the treatment of
frequent micturition, urgent micturition and urge
incontinence, peripheral anticholinergics, including
oxybutynin, propantheline, tolterodine and
hyoscyamine, are recommended. Cholinergics are
recommended for patients with detrusor areflexia.
However, these drugs should be used with caution,
as they can aggravate the motor symptoms of PD. If
urinary retention is present, intermittent
catheterization should be considered. If the urinary
retention is caused by prostate hypertrophy, surgical
intervention should be considered. Patients with
orthostatic hypotension need to increase their intake
of salt and water, to raise the head of their bed
during sleep and to avoid rising too quickly from a
lying or sitting position. Elastic leg stockings may
also be useful. Midodrine, a highly effective
α-adrenergic agonist, is recommended as the
first-choice drug [60, 63, 64]. Alternatively,
domperidone, a selective peripheral dopamine
antagonist, could be considered [65–67].
③Management of sleep disorders. Sleep disorders are
very common symptoms in PD patients. They
include insomnia, REM behavior disorder (RBD) and
excessive daytime sleepiness (EDS). Difficulty in
maintaining sleep (sleep fragmentation) is the most
common manifestation of insomnia. Frequent
waking may lead to the appearance of tremors
during the light-stage of sleep. Patients may be
unable to move, resulting in difficulties in turning
over or increased nocturia, which may be caused
by the loss of the dopaminergic action.
Supplementation of controlled-release levodopa,
dopamine agonists, or COMT inhibitors before
bedtime might be helpful if it is associated with PD
symptoms at night. For patients taking selegiline or
amantadine in the evening, the medication time
should be adjusted, i.e. selegiline should be taken in
the morning and at noon, and amantadine should
be taken at least before 16:00. If the sleep disorders
do not improve, reducing the dosage or even
discontinuing those drugs should be considered.
Alternatively, short-acting hypnotics or sedatives
could be recommended. For patients with RBD,
clonazepam can be taken at bedtime. EDS may be
related to the severity of PD and cognitive decline,
and can also be associated with the use of dopamine
agonists and levodopa. If sleepiness occurs after
taking medication, it may suggest overdosing;
therefore, reducing the dose may help to improve
EDS. Three RCTs have assessed the efficacy of
modafinil to treat EDS in PD. Based on these
studies, which had conflicting efficacy results
[68–70], there is insufficient evidence tocome to a
conclusion on the efficacy of modafinil for the
treatment of EDS in PD [65]. Only one study
examined the effects of methylphenidate (30 mg qd)
for the treatment of EDS or fatigue in PD in a
double-blind, placebo-controlled parallel-group
RCT [71]. Although results appear to be positive,
there is insufficient evidence to conclude that
methylphenidate is safe and efficacious for the
treatment of EDS or fatigue in PD [65]. Substituting
immediate-release levodopa with controlled-release
levodopa might help to avoid or reduce sleepiness
after medication.
④Management of sensory disturbances. The most
common sensory disturbances occurring in PD
patients are hyposmia, pain or numbness, and
restless legs syndrome (RLS) [6, 72]. Hyposmia is
likely to occur a number of years before the
appearance of motor symptoms [73, 74]. However,
there are no effective measures to improve it. Pain
or numbness is particularly common in patients
with advanced PD, and can be caused by the disease
itself, or by accompanied bone and joint lesions.
If pain or numbness can be relieved during the
on-period of medication, but recur during the
off-period, it might be caused by PD; thus, the long
half-life dopamine agonists or COMT inhibitors
should be recommended to prolong the on-period.
Alternatively, if it results from another cause,
relevant symptomatic therapies should be
implemented. For PD patients with RLS, taking a
dopamine agonist, e.g. pramipexole or ropinirole,
2 h before bedtime, is highly effective; levodopa is
also efficacious. Opioid drugs might be considered
for RLS refractory to dopaminergic drugs.
Surgical treatment
Surgical treatment should be considered when the motor
symptoms are not significantly improved and severe
motor fluctuations or dyskinesias occur. Nucleus lesion
and deep brain stimulation (DBS) are the main surgical
approaches for PD. DBS is the main choice because of
its non-invasive, safe and controllable advantages [44].
The indications for DBS intervention for PD include: (1)
Idiopathic PD with more than 5 years and Hoehn-Yahr
2.5–4; (2) age below 75 years old; (3) a good response to
levodopa/benseraside or levodopa/carbidopa at the early
stage of the disease (levodopa challenging test shows
more than 30 % improvement of motor symptoms evalu-
ated by UPDRS-III, although the efficacy of medication
is declining) [75–77]; (4) severe motor fluctuations or
dyskinesias occur, which affects the quality of the
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patient’s life; and (5) dementia and severe mental illness
must be excluded [78]. It should be emphasized that
DBS can only improve the motor symptoms signifi-
cantly, but does not cure the disease. Therefore, postop-
erative medication is still required,; however, the dosage
can be reduced. DBS shows good therapeutic efficacy for
limb tremor and/or muscular rigidity, but no significant
effect in PD patients with postural instability. DBS tar-
gets for PD include the subthalamic nucleus (STN) and
globus pallidus internus (GPi), and could significantly
improve tremor, muscular rigidity, bradykinesia and dys-
kinesias. A good preoperative response to levodopa
could serve as prognosis indicator for patients who have
undergone DBS of the STN (Level B evidence) [44],
while young patients with a short course of the disease
show better improvement than older patients with a
long course (Level C evidence) [44]. However, there is
no evidence for an association between GPi or VIM and
prognosis after DBS (Level U evidence) [44].
Exercise and other complementary management
Exercise and other complementary management strat-
egies, including Tai chi, Qi gong, yoga, massage, acupunc-
ture, dance and traditional herbs have shown efficacy in
improving the motor symptoms and even possibly delay-
ing disease progression [79–81]. They could be helpful to
PD patients with gait disorders, postural instability, lan-
guage disorders and dysphagia. In addition, persistent
training for language disorder, gait disorder and postural
instability might also help to improve the capacity for self-
care and motor function, and could prolong the duration
of the efficacy of medication [82–86].
Psychological counseling
Psychological disorders, such as anxiety and depression,
are common in PD patients. Anxiety and, particularly,
depression are important risk factors that affect the
quality of patient life and the effectiveness of PD medi-
cation [87–91]. They can occur before and after the on-
set of the motor symptoms of PD. Therefore, medication
should not only focus on improving the motor symp-
toms, but also on depression. Psychological counseling
and anti-depressants should be recommended to achieve
more satisfactory improvements.
Caring and nursing
Reasonable care and nursing assistances should be used
as adjunct treatment for controlling disease status and
for improving symptoms, in addition to professional
treatment of PD patients with medication. For example,
changing the diet composition and training swallowing
skills may be helpful for PD patients with dysphagia; and
using a straight strap by deputy chair and not using too
deep, too soft a chair or sofa are beneficial for PD
patients with difficulty in sitting and standing. These
measures could also avoid effectively accidents, such as
aspiration events and falling.
Conclusions
Parkinson’s disease is a highly complicated and incurable
disease, particularly in its advanced stage. In clinical
practice, guidelines for the management of PD are help-
ful to achieve optimal treatment for PD patients. More-
over, it is important to determine the status of dominant
symptoms and disease severity, how patients respond to
medication, including efficacy, on and off time and ad-
verse reactions, before making a treatment decision. As
different patients may have different dominant symp-
toms and different sensitivities to treatment, they will
have different medical requirements. In addition, the
same patient requires different treatment adjustments in
different stages of the disease; therefore, there are no
fixed patterns for the management of PD patients. Im-
portantly, it should be emphasized that the optimized
therapeutic efficacy can be achieved only if personalized
therapy and the therapeutic guidelines are adopted.
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